Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

106.13 -1.09 (-1.02%)
Official Closing Price Updated: 7:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,683,292
Open 106.35
Bid (Size) 106.10 (1)
Ask (Size) 107.82 (1)
Prev. Close 107.22
Today's Range 105.72 - 106.53
52wk Range 92.19 - 112.48
Shares Outstanding N/A
Dividend Yield 3.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Pharma Leader Beats on Earnings, But Shares Fall
Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
+5.08%
+5.08%
1 Month
+0.37%
+0.37%
3 Month
+12.47%
+12.47%
6 Month
-1.94%
-1.94%
1 Year
+0.95%
+0.95%

More News

Read More
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Via The Motley Fool
Novartis Reports Near 40% Margin In Q2; Shares Slide
Via Investor's Business Daily
Is NYSE:NVS a Good Fit for Dividend Investing?
Via Chartmill
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
Via Benzinga
Topics Stocks
Exposures US Equities
Novartis' Q2 Earnings: Revenue And EPS Beat, Raises 2024 Profit Forecast On Strong Demand For Key Drugs
Via Benzinga
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
Via Benzinga
Topics Economy
Exposures Interest Rates
Alnylam Stock Is a Blockbuster Biopharma In the Making
Via InvestorPlace
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
2 Magnificent Stocks to Buy With $500
Via The Motley Fool
D.R. Horton, Netflix And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
3 Global Stocks to Buy to Escape the Volatility on Wall Street
Via InvestorPlace
3 Spinoff Stocks You Should Buy Now: July 2024
Via InvestorPlace
Netflix, Goldman Sachs, J&J, ASML Lead Q2 Reports This Week As Analysts See Earnings Growth Accelerating To Fastest In Over 2 Years
Via Benzinga
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
Via InvestorPlace
3 Healthcare Stocks Injecting AI for Big Gains
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Novartis Stock Generating Improved Relative Strength
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
Mississippi Judge Upholds State Law Mandating Drug Discounts for Low-Income Patients
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.